S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
OTCMKTS:UCBJY

UCB (UCBJY) Stock Price, News & Analysis

$61.62
+0.05 (+0.08%)
(As of 03/28/2024 ET)
Today's Range
$61.26
$61.74
50-Day Range
$44.91
$62.45
52-Week Range
$34.85
$62.53
Volume
4,504 shs
Average Volume
11,564 shs
Market Capitalization
N/A
P/E Ratio
80.71
Dividend Yield
0.58%
Price Target
N/A
UCBJY stock logo

About UCB Stock (OTCMKTS:UCBJY)

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx for treating plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis; and Fintepla to treat Dravet syndrome. In addition, the company is involved in developing rozanolixizumab and Zilbrisq to treat myasthenia gravis; dapirolizumab pegol for systemic lupus erythematosus; fenfluramine to treat CDKL5 deficiency disorder; doxecitine for TK2 deficiency disorder; STACCATO alprazolam for stereotypical prolonged seizures; bepranemab to treat Alzheimer's disease; minzasolmin and UCB0222 for Parkinson's disease; and UCB1381 and UCB9741 for atropic dermatitis. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, and Otsuka. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.

UCBJY Stock Price History

UCBJY Stock News Headlines

Top Project Outperforms BTC in 2023…
According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.
Top Project Outperforms BTC in 2023…
According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.
UCB (UCBJY) Declares $0.73 Dividend
United Commercial Bank Ltd.
UCB SA (UCB.BR)
UCB's Rare Childhood Epilepsy Drug Scores FDA Approval
See More Headlines
Receive UCBJY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for UCB and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
OTCMKTS:UCBJY
Fax
N/A
Employees
8,450
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Jean-Christophe Tellier (Age 65)
    CEO & Executive Director
    Comp: $4.45M
  • Ms. Sandrine Dufour CFA (Age 58)
    Executive VP, CFO & Chief Corporate Development
  • Dr. Kirsten Lund-Jurgensen Ph.D. (Age 64)
    Executive Vice President of Supply & Technology Solutions
  • Dr. Dhavalkumar D. Patel M.D. (Age 63)
    Ph.D., Executive VP & Chief Scientific Officer
  • Ms. Denelle J. Waynick Johnson J.D. (Age 57)
    Executive VP & General Counsel
  • Mr. Jean-Luc Fleurial (Age 59)
    Executive VP & Chief Human Resources Officer
  • Prof. Iris Low-Friedrich (Age 64)
    Executive VP & Chief Medical Officer
  • Mr. Emmanuel Caeymaex (Age 55)
    Executive VP of Immunology Solutions & Head of US
  • Ms. Caroline Vancoillie
    Chief Accounting Officer, Head of Group Finance & CFO of Patient Value Functions
  • Antje Witte
    Head of Investor Relations

UCBJY Stock Analysis - Frequently Asked Questions

Should I buy or sell UCB stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for UCB in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" UCBJY shares.
View UCBJY analyst ratings
or view top-rated stocks.

How have UCBJY shares performed in 2024?

UCB's stock was trading at $43.60 at the start of the year. Since then, UCBJY stock has increased by 41.3% and is now trading at $61.6150.
View the best growth stocks for 2024 here
.

Are investors shorting UCB?

UCB saw a decrease in short interest during the month of March. As of March 15th, there was short interest totaling 700 shares, a decrease of 90.0% from the February 29th total of 7,000 shares. Based on an average daily trading volume, of 14,300 shares, the short-interest ratio is presently 0.0 days.
View UCB's Short Interest
.

How often does UCB pay dividends? What is the dividend yield for UCB?

UCB announced a dividend on Wednesday, April 26th. Stockholders of record on Tuesday, May 2nd will be paid a dividend of $0.4583 per share on Thursday, May 18th. This represents a yield of 0.95%. The ex-dividend date of this dividend is Monday, May 1st. This is a boost from the stock's previous dividend of $0.44.
Read our dividend analysis for UCBJY
.

Is UCB a good dividend stock?

UCB (OTCMKTS:UCBJY) pays an annual dividend of $0.36 per share and currently has a dividend yield of 1.26%. The dividend payout ratio is 46.55%. This payout ratio is at a healthy, sustainable level, below 75%.
Read our dividend analysis for UCBJY.

How do I buy shares of UCB?

Shares of UCBJY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:UCBJY) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners